PCOS Is Now PMOS: What the New Name Means and Which Blood Tests Diagnose It

On 12 May 2026 the condition known for nearly a century as polycystic ovary syndrome was given a new global name: polyendocrine metabolic ovarian syndrome, or PMOS. The change came out of a three-year consensus process led by the international guideline group, with 56 academic, clinical and patient organisations — the Endocrine Society among them — and more than 14,000 survey responses from people with the condition and the professionals who treat them. It was published in The Lancet the same day.

The reason is in the old name. “Polycystic” suggested a disease of ovarian cysts, when the follicles seen on ultrasound are not pathological cysts and many people with the condition have normal-looking ovaries; the companion analysis found no increase in abnormal ovarian cysts at all. Meanwhile the features that actually drive health outcomes — excess androgens, insulin resistance, weight and metabolic risk, mood, skin and fertility effects — were nowhere in the name. The result, the consensus group argued, was delayed diagnosis, fragmented care and stigma. “Polyendocrine metabolic ovarian” names the three systems involved.

A three-year transition is under way: journals, guidelines and health systems are moving to PMOS, with full adoption planned for the 2028 international guideline update. NICE has already retitled its draft guideline. You will see both names for a while, and your own records may still say PCOS. Nothing about your diagnosis, treatment or testing changes because of the name.

Diagnosis in adults still rests on two of three features, with other causes excluded: irregular or absent ovulation (cycles shorter than 21 or longer than 35 days, or fewer than eight a year), excess androgens — shown clinically by hirsutism, acne or androgenic hair loss, or biochemically by a raised testosterone — and polycystic ovarian morphology on ultrasound, for which a raised AMH is now an accepted alternative in adults. In adolescents the ultrasound and AMH criteria are not used; both irregular cycles and androgen excess are required.

“Other causes excluded” is where most of the blood work earns its place. Thyroid disease, high prolactin, non-classic congenital adrenal hyperplasia, Cushing syndrome and androgen-secreting tumours can all produce irregular cycles or androgen excess, and each is found with a specific test. A work-up that skips them can label someone with PMOS who has a different, often more treatable, condition.

Test	What it answers	Notes
Total and free testosterone	Is there biochemical androgen excess?	Mass-spectrometry (LC-MS/MS) assays are preferred in women because immunoassays overestimate at low levels; free testosterone or the free androgen index adds sensitivity
SHBG	How much testosterone is biologically active	Low SHBG is typical with insulin resistance and raises free testosterone
DHEA-S	Adrenal androgen contribution	Markedly high values point away from PMOS toward an adrenal cause
LH and FSH	Pituitary pattern	A raised LH:FSH ratio is common but is no longer a diagnostic criterion; FSH also screens for ovarian insufficiency
Prolactin and TSH	Exclusions	High prolactin and thyroid disease both cause irregular cycles
17-hydroxyprogesterone (morning, follicular)	Exclusion of non-classic CAH	Ordered by a clinician when androgens are high
Fasting insulin, fasting glucose, A1c	The metabolic half: insulin resistance and glucose status	Recommended at diagnosis and periodically after; HOMA-IR is calculated from insulin and glucose
Lipid panel	Cardiovascular risk	Recommended at diagnosis regardless of weight
AMH	Ultrasound alternative in adults	Not for adolescents; not used alone

Timing matters for several of these. LH, FSH and estradiol are read on cycle day 2–4 when periods occur; testosterone and 17-hydroxyprogesterone are drawn in the morning; insulin and glucose are fasting. Hormonal contraception suppresses androgens and gonadotropins and makes the hormone results uninterpretable, so testing is done off it (typically after three months) or interpreted with that caveat.

Insulin resistance is present in a majority of people with PMOS, including many at a normal weight, and it is the mechanism behind much of the condition: high insulin drives the ovaries and adrenals to make more androgens and lowers SHBG, which raises the active fraction further. It is also what carries the long-term risks — type 2 diabetes, fatty liver, sleep apnoea and cardiovascular disease — which is why the international guideline recommends glucose testing (an oral glucose tolerance test, A1c or fasting glucose) at diagnosis and every one to three years, and a lipid panel at diagnosis.

Fasting insulin is not formally part of the diagnostic criteria, but with fasting glucose it gives HOMA-IR, a widely used estimate of insulin resistance that many clinicians track to guide lifestyle, metformin or GLP-1 decisions. The Insulin Resistance Panel bundles insulin, glucose and A1c for exactly that purpose; the PCOS Panel includes insulin and A1c alongside the hormones.

Every test above except 17-hydroxyprogesterone can be ordered online and drawn at a Quest or Labcorp patient service center after a licensed physician reviews the order; results post to your portal in one to five business days and can be shared with your clinician. The PCOS Panel — renamed in our catalog to carry both names — covers total and free testosterone, DHEA-S, LH, FSH, prolactin, SHBG, fasting insulin, A1c and TSH in one draw. The results do not make the diagnosis on their own: the criteria require your cycle history and examination, and the exclusions are a clinical judgement. What the blood work does is arrive at that appointment with the numbers already in hand.